"...This combination is tailored for patients whose tumors express CCR5 and who have already undergone multiple lines of treatment, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, as well as anti-VEGF and anti-EGFR therapies when appropriate."

https://www.targetedonc.com/view/fda-clears-p...stable-crc
Sorry if already discussed. Does this tailoring insure that those genetically inappropriate to the goals are excluded so as not to dilute efficacy? TIA.